Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-06-14 DOI:10.1080/14796694.2025.2516410

Franco Antonio, Luisa Carbognin, Ida Paris, Alba Di Leone, Armando Orlandi, Fabio Marazzi, Antonino Mule, Paolo Belli, Alessandro Rossi, Stefano Magno, Antonella Palazzo, Valeria Masiello, Angela Santoro, Paola Fuso, Emilio Bria, Sabatino D'Archi, Lorenzo Scardina, Alejandro Martin Sanchez, Diana Giannarelli, Stefano Paternello, Giorgia Garganese, Giovanni Scambia, Giampaolo Tortora, Riccardo Masetti, Gianluca Franceschini, Alessandra Fabi

{"title":"Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study.","authors":"Franco Antonio, Luisa Carbognin, Ida Paris, Alba Di Leone, Armando Orlandi, Fabio Marazzi, Antonino Mule, Paolo Belli, Alessandro Rossi, Stefano Magno, Antonella Palazzo, Valeria Masiello, Angela Santoro, Paola Fuso, Emilio Bria, Sabatino D'Archi, Lorenzo Scardina, Alejandro Martin Sanchez, Diana Giannarelli, Stefano Paternello, Giorgia Garganese, Giovanni Scambia, Giampaolo Tortora, Riccardo Masetti, Gianluca Franceschini, Alessandra Fabi","doi":"10.1080/14796694.2025.2516410","DOIUrl":null,"url":null,"abstract":"Background: Neoadjuvant chemotherapy (NACT) improves oncologic and cosmetic outcomes in breast cancer (BC), yet recurrence remains a concern. This study identifies factors associated with recurrence at 3 and 5 years in BC patients receiving NACT.Methods: A retrospective analysis of 933 stage I - III BC patients (2014-2021) evaluated event-free survival (EFS) predictors using multivariate analyses.Results: Lower 5-year EFS was linked to axillary staging (cN, p < 0.001), molecular subtype (p < 0.001), surgery type (p = 0.030), and post-surgical nodal status (ypN, p = 0.005). High recurrence risk was observed with aggressive tumor biology, advanced disease, and residual nodal burden, while favorable responses correlated with better outcomes.Conclusion: Biological and clinical factors guide post-NACT strategies to reduce recurrence in high-risk BC patients.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-9"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2516410","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Neoadjuvant chemotherapy (NACT) improves oncologic and cosmetic outcomes in breast cancer (BC), yet recurrence remains a concern. This study identifies factors associated with recurrence at 3 and 5 years in BC patients receiving NACT.

Methods: A retrospective analysis of 933 stage I - III BC patients (2014-2021) evaluated event-free survival (EFS) predictors using multivariate analyses.

Results: Lower 5-year EFS was linked to axillary staging (cN, p < 0.001), molecular subtype (p < 0.001), surgery type (p = 0.030), and post-surgical nodal status (ypN, p = 0.005). High recurrence risk was observed with aggressive tumor biology, advanced disease, and residual nodal burden, while favorable responses correlated with better outcomes.

Conclusion: Biological and clinical factors guide post-NACT strategies to reduce recurrence in high-risk BC patients.

查看原文本刊更多论文

新辅助治疗后乳腺癌复发的预测危险因素：NEORISK研究

背景：新辅助化疗（NACT）改善了乳腺癌（BC）的肿瘤学和美容结果，但复发仍然是一个问题。本研究确定了接受NACT治疗的BC患者3年和5年复发的相关因素。方法：回顾性分析933例I - III期BC患者（2014-2021），使用多变量分析评估无事件生存（EFS）预测因子。结果：较低的5年EFS与腋窝分期（cN, p p = 0.030）和术后淋巴结状态（ypN, p = 0.005）有关。肿瘤生物学上具有侵袭性、疾病进展和残余淋巴结负担时，观察到高复发风险，而良好的反应与较好的结果相关。结论：生物学和临床因素指导nact后策略减少高危BC患者的复发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.